Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

Figure 1. Flow of enrollment, allocation, follow up and analysis in this study. Data are the number of study participants. A total of 110 patients are randomly assigned to receive pioglitazone, glimepiride or dapagliflozin, and finally the data of 98 participants are evaluated in this study.

Figure 2. Changes of the liver‐to‐spleen (L/S) ratio on computed tomography from baseline to 28 weeks. (a) The percentage of participants whose L/S ratio was increased and (b) the degree of changes in the L/S ratio in each group. The L/S ratio was increased after the treatment with dapagliflozin (Dapa) and pioglitazone (Pio), but not with glimepiride (Gli). The Kruskal–Wallis and Steel–Dwass methods were used for the comparison among three unpaired groups. § P < 0.05 versus glimepiride.